An investigation for investors in CEL-SCI Corporation (NYSE:CVM) shares over potential securities laws violations by CEL-SCI Corporation was announced.

San Diego, CA -- (SBWire) -- 07/13/2021 --CEL-SCI Corporation is under investigation concerning potential securities laws violations in connection with certain financial statements.

Investors who purchased shares of CEL-SCI Corporation (NYSE: CVM), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by CEL-SCI Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Vienna, VA based CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. CEL-SCI Corporation reported that its Net Loss increased from $22.13 million for the 12 months period that ended on September 30, 2019 to $30.25 million for the 12 months period that ended on September 30, 2020. On June 28, 2021, CEL-SCI Corporation announced that the Phase 3 study for the Company's Multikine (leukocyte interleukin) immunotherapy candidate missed its primary endpoint for primary (previously untreated) squamous cell carcinoma of the head and neck. Shares of CEL-SCI Corporation (NYSE: CVM) declined from $27.28 per share June 28, 201 to as low as $7.08 per share on July 2, 2021.

Those who purchased shares of CEL-SCI Corporation (NYSE: CVM), have certain options and should contact the Shareholders Foundation.